PMID- 19860536
OWN - NLM
STAT- MEDLINE
DCOM- 20100217
LR  - 20220321
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 8
IP  - 6
DP  - 2009 Nov
TI  - Safety evaluation of enoxaparin in currently approved indications.
PG  - 745-54
LID - 10.1517/14740330903352498 [doi]
AB  - BACKGROUND: Potential limitations of unfractionated heparin (UFH) have prompted a 
      search for new antithrombin therapies in recent years. Enoxaparin has shown 
      similar or improved efficacy when compared with UFH, but it has been associated 
      with safety concerns of increased bleeding in patients with acute coronary 
      syndromes in some studies. OBJECTIVE: This narrative review focuses on the safety 
      and tolerability of enoxaparin in adult patients in the setting of currently 
      approved indications. METHODS: Synthesis of evidence from recent trials, 
      systematic reviews, meta-analyses, regulatory documents and clinical trials 
      registries of manufacturers. CONCLUSION: Enoxaparin can be considered for 
      prophylaxis and treatment of a wide range of thrombotic conditions as an 
      alternative to UFH with a clinically modest increase in bleeding complications, 
      without altering the risk-benefit profile of this compound. Selection of the 
      appropriate dosage is strongly recommended. Special precautions should be taken 
      in specific populations that are at higher risk of bleeding, such as patients 
      with renal dysfunction and elderly patients, where dose adjustment is 
      recommended.
FAU - Meneveau, Nicolas
AU  - Meneveau N
AD  - University Hospital Jean Minjoz, Department of Cardiology, Besancon, France. 
      nicolas.meneveau@univ-fcomte.fr
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Anticoagulants/*adverse effects/pharmacology/*therapeutic use
MH  - Enoxaparin/*adverse effects/pharmacology/*therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced/epidemiology
MH  - Humans
MH  - Myocardial Infarction/complications/drug therapy
MH  - Postoperative Complications/prevention & control
MH  - Pregnancy
MH  - Randomized Controlled Trials as Topic
MH  - Venous Thromboembolism/prevention & control
RF  - 65
EDAT- 2009/10/29 06:00
MHDA- 2010/02/18 06:00
CRDT- 2009/10/29 06:00
PHST- 2009/10/29 06:00 [entrez]
PHST- 2009/10/29 06:00 [pubmed]
PHST- 2010/02/18 06:00 [medline]
AID - 10.1517/14740330903352498 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2009 Nov;8(6):745-54. doi: 10.1517/14740330903352498.